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Background-—Plasminogen activator inhibitor type 1 (PAI-1) plays an essential role in the ﬁbrinolysis system and thrombosis.
Population studies have reported that blood PAI-1 levels are associated with increased risk of coronary heart disease (CHD).
However, it is unclear whether the association reﬂects a causal inﬂuence of PAI-1 on CHD risk.
Methods and Results-—To evaluate the association between PAI-1 and CHD, we applied a 3-step strategy. First, we investigated
the observational association between PAI-1 and CHD incidence using a systematic review based on a literature search for PAI-1
and CHD studies. Second, we explored the causal association between PAI-1 and CHD using a Mendelian randomization approach
using summary statistics from large genome-wide association studies. Finally, we explored the causal effect of PAI-1 on
cardiovascular risk factors including metabolic and subclinical atherosclerosis measures. In the systematic meta-analysis, the
highest quantile of blood PAI-1 level was associated with higher CHD risk comparing with the lowest quantile (odds ratio=2.17; 95%
CI: 1.53, 3.07) in an age- and sex-adjusted model. The effect size was reduced in studies using a multivariable-adjusted model
(odds ratio=1.46; 95% CI: 1.13, 1.88). The Mendelian randomization analyses suggested a causal effect of increased PAI-1 level on
CHD risk (odds ratio=1.22 per unit increase of log-transformed PAI-1; 95% CI: 1.01, 1.47). In addition, we also detected a causal
effect of PAI-1 on elevating blood glucose and high-density lipoprotein cholesterol.
Conclusions-—Our study indicates a causal effect of elevated PAI-1 level on CHD risk, which may be mediated by glucose
dysfunction. ( J Am Heart Assoc. 2017;6:e004918. DOI: 10.1161/JAHA.116.004918.)
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P lasminogen activator inhibitor type 1 (PAI-1) is themajor inhibitor of the ﬁbrinolytic system. It inhibits the
effect of plasminogen activators, thereby inhibiting plasmin
formation and downregulating breakdown of ﬁbrin clots.
PAI-1 deﬁciency caused by mutations has been reported to
lead to a moderate bleeding disorder.1 On the ﬂip side, high
levels of PAI-1 were reported in some families with
thrombophilia.2,3 Blood PAI-1 antigen levels and activity are
strongly correlated and both measures have been used to
study the role of PAI-1 in cardiovascular disease. Elevated
PAI-1 levels have been observed to be associated with
reinfarction and coronary heart disease (CHD) generally.4
Furthermore, circumventing PAI-1 actions by administering
tissue plasminogen activator, one of the key targets
inhibited by PAI-1, is an important treatment for acute
ischemic stroke.5
However, the relationship between PAI-1 and early
atherosclerosis and incident CHD remains unclear. Previous
studies reported the correlation of PAI-1 with multiple
conventional risk factors of CHD, eg, obesity, glycemic traits,
and type 2 diabetes mellitus,6 metabolic syndrome,7 as well
as correlation with vessel wall thickness.8 In addition, higher
PAI-1 expression was observed in coronary artery tissues in
the presence of atherogenic lesions.9,10 These ﬁndings raise
interest in whether PAI-1 plays a role in early atherosclerosis
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versus acute thrombosis. The association of elevated plasma
PAI-1 levels with CHD incidence has been reported in
longitudinal studies.11–19 However, this association did not
always remain consistent after adjusting for cardiovascular
risk factors.11–14,16–23 On the one hand, these inconsistencies
could be due to small sample sizes and/or restricted study
populations (eg, type 2 diabetes mellitus patients, obese
individuals, or HIV patients).20,24 On the other hand, the
original observational associations including the link between
PAI-1 and CHD are potentially prone to bias from unmeasured
confounders or overadjustment for mediators.
To overcome these obstacles, epidemiological studies have
adapted instrumental variable (IV) analysis to assess causality
and to limit confounding through the use of single nucleotide
polymorphisms (SNPs) as IV. This method is referred to as the
Mendelian randomization (MR) approach.25 Given that geno-
types are assigned randomly from parents to offspring during
meiosis, the causal effect of PAI-1 onCHD risk can be estimated
by the ratio of a SNP(IV)-PAI-1 association to SNP(IV)-CHD
association.25,26 Using the MR method, a previous study
suggested a causal association of PAI-1 with myocardial
infarction and blood triglycerides.27 However, in that study,
the association of the SNP, the “4G/5G” polymorphism
(rs1799889) in SERPINE1, with PAI-1 and CHD risk was based
on a meta-analysis using published candidate gene studies
between 1993 and 2010.27 Those observations could be
inﬂuenced by publication bias, small sample sizes and testing
of a single SNP IV. With the recent advent of large-scale genetic
studies, an updated view of potential causal associations
betweenPAI-1,CHD,and its risk factors iswarranted, andshould
have better power to untangle potential causal pathways.
In the largest genome-wide association study (GWAS) for
PAI-1 (n=19 599 individuals of European ancestry), the
CHARGE Hemostatic Working Group reported 4 independent
genetic variants from 3 loci (chr7q22.1, chr11p15.2,
chr3p25.2).28 The strongest ﬁnding in the study was the
SERPINE1 gene locus, the coding gene region of PAI-1, on
chr7q22.1. The lead SNP rs2227631 is in the promoter region
of SERPINE1 and highly correlated with the well-characterized
functional variant 4G/5G SERPINE1 polymorphism (r2=0.78).
Following conditional analysis for the lead SNP, a second
independent signal (rs6976053) in the same chr7q22.1 locus
was observed 200 kb upstream of rs2227631.28 In total, the
genetic variants from the 3 identiﬁed loci explained 0.9%
variation of plasma PAI-1 levels in the Framingham Heart
Study.28 This strength of IV is in the range of others that have
been employed in successful MR studies, suggesting these
variants could serve as a potential IV in MR analyses with risk
factor, subclinical, and clinical outcomes.26,29,30
In this investigation, we aimed to understand whether
plasma PAI-1 levels played a causal role in CHD risk. To
achieve the goal, we ﬁrst investigated the observational
association between PAI-1 and CHD using a systematic meta-
analysis. We then explored the causal effect of PAI-1 on CHD
using a MR approach. Finally, we further investigated the
causal effect of PAI-1 on known cardiovascular risk factors,
including metabolic risk factors (ie, type 2 diabetes mellitus,
body mass index [BMI], waist-hip ratio, fasting blood glucose,
insulin and lipids, and blood pressure) and subclinical
atherosclerosis measures (ie, carotid intima-media thickness,
carotid plaque volume, and coronary artery calciﬁcation).
Methods
Systematic Meta-Analysis for Observational
Association
We applied a systematic review to understand the observa-
tional association of PAI-1 with CHD. An electronic literature
search was conducted in PubMed by 2 researchers indepen-
dently using the following criteria: (1) including “Coronary
heart disease” or “Coronary artery disease” or “Myocardial
infarction”; (2) including “plasminogen activator inhibitor type
1”; (3) published in English from January 1992 to April 2016;
and (4) study in human subjects. Two reviewers independently
performed the literature screen and found consistent results.
In total, we found 1228 articles available in PubMed. There
were 33 publications that reported an effect size of PAI-1 on
CHD. To focus on association between PAI-1 and incident
CHD, we excluded those studies that reported prevalent CHD
(13 publications), recurrent CHD (5 publications), or stroke
(1 publication). In addition, considering that the majority of
publications reported the relative risk of CHD comparing the
highest (ie, tertile, quartile, or quintile) with the lowest
quantile, we included only publications using categorical
analyses of PAI-1. Ten studies that adjusted only for age and
sex reported association between PAI-1 and CHD incidence
(Table S1), while 13 studies found the same association
following adjustment for multiple covariates (eg, BMI, blood
glucose, blood lipids, and blood pressure; Table S1).11–23,31
Covariates used in each study that included multivariable-
adjusted models are shown in Table S1. Detailed literature
screening procedure is presented in Figure 1. A random-effect
meta-analysis was applied in each group of studies using the
“metan” package in STATA 13.1.
Instrumental Variable Analysis for Causal
Association
A genetic variant acts as an IV if it fulﬁls the following
assumptions: (1) the genetic variant is associated with the
exposure; and (2) the genetic variant can only inﬂuence the
outcome through the exposure.32 Burgess et al reported that
MR can be applied for causal association using summary
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genetic statistics, ie, beta coefﬁcients with standard errors
from genetic association studies.25 An MR approach using
summary data can take advantage of the statistical power of
large sample sizes of previous GWASs and does not require
multiple phenotypes to be measured in the same study
sample. We conducted a power calculation (https://sb452.
shinyapps.io/power/) for a PAI-1 IV (explaining 0.9% of
variance).28 The results suggest we have 80% statistical power
to ﬁnd a causal odds ratio (OR) larger than 1.15. Thus, we
considered the MR analyses viable and obtained summary
statistics for circulating PAI-1 levels, CHD and CHD risk
factors from previous GWASs as listed in Table 1. These are
based on the largest GWAS meta-analysis for each phenotype
at the time of analysis and primarily conducted on European
ancestry samples.28,33–42
We applied 2 sets of genetic variants as IVs. First, we
selected multiple genetic variants from the PAI-1 locus
chr7q22.1 (SERPINE1). In this step, we selected SNPs in this
locus that were associated with PAI-1 (P<19106) and that
were only moderately correlated with each other after
iterative stepwise selection (r2<0.5 each round). The corre-
lations between SNPs were obtained from the bioinformatics
tool SNiPA using data from the 1000 Genomes phase 3,
European reference population.43 This resulted in 4 selected
SNPs (rs2227631, rs2075756, rs12672665, and rs757718;
Table S2). A genetic risk score as IV was then constructed by
adding the number of risk alleles and weighting each risk
allele dose by its effect on PAI-1. We further corrected for the
correlation between each SNP in this genetic risk score in our
IV analysis following the method developed by Burgess
et al.44 In the second step, we extended the genetic risk
score by using multiple loci from the PAI-1 GWAS that were
shown to reach genome-wide signiﬁcance (P<59108). Four
independent SNPs reported from the PAI-1 GWAS were used
in the IV (rs2227631, rs6976053, rs6486122, and
rs11128603; Table S2),28 and then a genetic risk score was
generated as IV by adding the counts of risk alleles weighted
by their effects on PAI-1. The second IV was only applied for
the causal association between PAI-1 and CHD, but not
between PAI-1 and cardiovascular risk factors.
The estimates for associations of SNPs with PAI-1 are
reported per risk allele change of units of log-transformed PAI-
1.28 The estimates for associations of SNPs with CHD are
reported per risk allele change of CHD risk.39 The causal
effect of a per unit change of log-transformed PAI-1 on CHD is
estimated as the per risk allele change of CHD risk dependent
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Figure 1. Flow chart for article selection in systematic meta-analysis. CHD indicates coronary heart
disease.
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on the per risk allele change of log-transformed PAI-1 units.
When using 1 SNP as an IV, it is calculated as the ratio
estimate of the SNP-CHD association to the SNP-PAI-1, that
is, bSNP-CHD association/bSNP-PAI-1 association.
26 When using mul-
tiple SNPs as an IV, the combined causal effect was evaluated
as the inverse-variance weighted estimate of the causal ratio
when using each SNP alone as an IV.25 The 95% CIs for causal
estimates are calculated based on the estimates (beta/log-
transformed OR) and SE: estimate1.969SE. The IV analysis
was performed using R version 3.1.2.
Results
In the systematic review, most previous studies reported PAI-
1 and CHD incidence association based on PAI-1 levels in
quartiles, while there were 3 studies based on dichotomizing
PAI-1 levels, 3 using tertiles and 2 using quintiles. A pooled
meta-analysis shows the highest quantile (ie, tertile, quartile,
or quintile) of blood PAI-1 levels is associated with higher risk
of CHD incidence compared with the lowest quantile
(OR=2.17; 95% CI: 1.53, 3.07; Figure 2A) in an age-and sex-
adjusted model.11–19,22 The overall heterogeneity across
studies is high (I2=71.5%, P<0.001; Figure 2A). The associa-
tion estimate is reduced but remains signiﬁcant in studies
using a multivariable-adjusted model (OR=1.46; 95% CI: 1.13,
1.88; Figure 2B),11–14,16–23,31 with a lower overall hetero-
geneity compared with studies applying only an age-and sex-
adjusted model (I2=55.7%, P=0.008; Figure 2B). In the
subgroup meta-analysis based on different PAI-1 quantile
scales, heterogeneity is observed most strongly in the quartile
subgroup in both age- and sex-adjusted model (I2=81.6%,
P<0.001; Figure 2A) and the multivariable-adjusted model
(I2=61.7%, P<0.016; Figure 2B).
Using variants in the SERPINE1 locus as IVs, the MR
analysis suggests that, under the assumptions of the MR
approach, an increase of one unit of log-transformed PAI-1
level can increase CHD risk by 22% (OR=1.22; 95% CI: 1.02,
1.45; Table 2). When variants in multiple loci are used as IVs,
the result is consistent and the conﬁdence interval narrows
slightly (OR=1.25; 95% CI: 1.07, 1.45). We constructed
scatter plots for genetic associations with CHD against
genetic associations with PAI-1 for the 2 sets of SNPs as IV
separately (Figure 3). Figure 3A shows that all SNPs from the
SERPINE1 locus are associated with PAI-1 and CHD in a
Table 1. List of Genome-Wide Association Studies Used in the Current Study
Trait Consortium Sample Sizes Unit Transformation Reference
SNP association with the exposure
PAI-1 CHARGE 19 599 ng/mL log-transformed Huang et al28
SNP association with the primary outcome
CHD* CARDIOGRAMplusC4D 60 801/123 504† Case/control N/A Nikpay et al39
SNP association with the potential intermediators via metabolic syndrome
Type 2 diabetes mellitus DIAGRAM 34 840/114 981† Case/control N/A Morris et al38
Fasting blood glucose MAGIC 58 074 mmol/L N/A Manning et al37
Fasting blood insulin MAGIC 51 750 pmol/L Log-transformed Manning et al37
Blood lipids‡ GLGC 188 577 mmol/L Quantile normalization Willer et al42
Blood pressure§ ICBP 203 056 mm Hg Inverse standard normalization Ehret et al35
BMI GIANT 339 224 kg/m2 Inverse standard normalization Locke et al36
Waist–hip ratio GIANT 224 459 cm/cm Inverse standard normalization Shungin et al41
Adiponectin ADIPOGen 39 883 lg/mL Log-transformed Dastani et al34
SNP association with the potential intermediators via early atherosclerosis
IMT CHARGE 31 211 mm Log-transformed Bis et al33
Carotid plaquek CHARGE 12 955/18 263† Case/control N/A Bis et al33
CAC CHARGE 9961 Agatston score Log-transformed O’Donnell et al40
BMI indicates body mass index; CAC, coronary artery calciﬁcation; CHD, coronary heart disease; IMT, intima-media thickness; N/A, not applicable; PAI-1, plasminogen activator type 1;
SNP, single nucleotide polymorphism.
*CHD cases include myocardial infarction and unstable angina.
†Sample sizes of CHD, type 2 diabetes mellitus, and plaque are split into cases and controls.
‡Blood lipids includes serum total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides.
§Blood pressure includes systolic blood pressure and diastolic blood pressure measures.
kPlaque cases are individuals with presence of carotid plaque.
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Overall  (I-squared = 71.5%, p = 0.000)
StudyA
B
Tofler et al, 2016
Cushman et al, 1999
Söderberg et al, 1999
Meltzer et al, 2010
Folsom et al, 2001
Tertiles
Thøgersen et al, 2009
Thøgersen et al, 2004
Thögersen et al, 1998
Subtotal  (I-squared = 81.6%, p = 0.000)
Quintiles
Smith et al, 2005
Subtotal  (I-squared = .%, p = .)
Subtotal  (I-squared = .%, p = .)
Quartiles
Subtotal  (I-squared = 19.2%, p = 0.266)



































Overall  (I-squared = 55.7%, p = 0.008)
Tertiles
Smith et al, 2005
Subtotal  (I-squared = 0.0%, p = 0.392)
Yano et al, 2013
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Meltzer et al, 2010
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Knudsen et al, 2014
Thögersen et al, 1998
Subtotal  (I-squared = 67.1%, p = 0.016)
Subtotal  (I-squared = 48.7%, p = 0.163)
De Luca et al, 2013
Folsom et al, 2001
Subtotal  (I-squared = 0.0%, p = 0.537)
Söderberg et al, 1999
Tofler et al, 2016
Cushman et al, 1999
Luc et al, 2010





































Figure 2. Observational associations of PAI-1 and CHD from the literature up until July 2016. This is a
forest plot depicting the result of the meta-analysis based on previous publications for observations of
plasminogen activator inhibitor type 1 (PAI-1) and coronary heart disease (CHD) association. Odds ratio
(OR) with 95% CI is the OR of CHD comparing the highest PAI-1 quantile to lowest PAI-1 quantile, which is
also represented as a point with bar in the plot. The diamond represents the meta-analysis result using a
random effects model. A, PAI-1-CHD associations adjusted for age, sex, and ethnic group in each study. B,
PAI-1-CHD association in models adjusted for multiple CHD risk factors.
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similar manner. That is, when one SNP has a larger effect size
on PAI-1, it also has a relatively larger effect size on CHD risk.
This suggests that the results using the combined genetic risk
score in set 1 (SERPINE1 locus) as IV are not simply driven by
a single SNP. Similarly, Figure 3B suggests that the results
when using multiple loci in the IV are not driven by a single
SNP.
MR analyses for causal effects of PAI-1 on cardiovascular
risk factors using variants in the SERPINE1 locus alone
suggest that an increase of 1 unit of log-transformed PAI-1
level increases circulating fasting glucose levels by
0.08 mmol/L (b=0.08; 95% CI: 0.02, 0.14; Table 2); and
increases high-density lipoprotein cholesterol (HDL-C) by 0.13
SDs (b=0.13; 95% CI: 0.04, 0.23; Table 2). We found no
evidence for causal effects of PAI-1 on other metabolic risk
factors, or subclinical atherosclerosis. However, the result for
BMI suggests a negative effect of PAI-1 on BMI with a trend
toward signiﬁcance (b=0.07, P=0.070; Table 2), which
contradicts most epidemiological studies demonstrating a
positive association.45,46 Therefore, we further investigated
the causal effect of BMI on PAI-1 levels using 77 genome-wide
signiﬁcant loci identiﬁed in a large BMI GWAS in European
populations (Data S1).36 This result shows that BMI has a
causal effect on PAI-1 in the positive direction (b: 0.21; 95%
CI: 0.13, 0.29; Table S3), and was consistent with sensitivity
analyses using a median estimator approach and MR-Egger
regression to test for potential pleiotropic effects.
Discussion
The systematic meta-analysis using the available epidemio-
logical literature supports the association between PAI-1 and
Table 2. Causal Effect of PAI-1 on Cardiovascular Risk
Factors Using the SERPINE1 Locus as IV
Trait Effect 95% CI P Value
CHD* 1.22 (1.01, 1.47) 0.039
Metabolic risk factors
Type 2 diabetes mellitus* 1.18 (0.85, 1.62) 0.321
Fasting blood glucose 0.08 (0.02, 0.14) 0.012
Fasting blood insulin 0.002 (0.07, 0.06) 0.939
Total cholesterol 0.08 (0.02, 0.19) 0.113
HDL-C 0.13 (0.04, 0.23) 0.008
LDL-C 0.03 (0.08, 0.13) 0.583
Triglycerides 0.03 (0.12, 0.23) 0.578
BMI 0.07 (0.14, 0.01) 0.070
Waist–hip ratio 0.07 (0.15, 0.02) 0.112
Systolic blood pressure 1.22 (0.77, 3.20) 0.230
Diastolic blood pressure 0.20 (1.06, 1.46) 0.758
Adiponectin 0.004 (0.08, 0.09) 0.926
Subclinical atherosclerosis
IMT 0.01 (0.02, 0.04) 0.669
Carotid plaque* 1.03 (0.98, 1.58) 0.876
CAC 0.33 (0.29, 0.95) 0.293
BMI indicates body mass index; CAC, coronary artery calciﬁcation; CHD, coronary heart
disease; HDL-C, high-density lipoprotein cholesterol; IMT, intima-media thickness; IV,
instrumental variable; LDL-C, low-density lipoprotein cholesterol; PAI-1, plasminogen
activator type 1.
*The traits with marked with * are dichotomous traits and effects/95% CI for these traits
were reported as odds ratio. Other traits are all continuous traits, and their effects/95%
CI were reported as beta coefﬁcients.
Figure 3. Scatter plots for genetic associations with CHD
against genetic associations with PAI-1. This shows scatter plots
of genetic associations with coronary heart disease (CHD) against
genetic associations with plasminogen activator inhibitor type 1
(PAI-1). Lines in the horizontal and vertical directions represent
95% CI of genetic associations with PAI-1 and CHD, respectively.
The SNP marked in red (rs2227631) located in SERPINE1 is the
SNP with the lowest P-value reported in the genome-wide
association study of PAI-1.28 A, Scatter plot of 4 correlated SNPs
selected in the SERPINE1 locus as instrumental variable. B, Scatter
plot of 4 independent SNPs selected from multiple loci as
instrumental variable. SNP indicates single nucleotide
polymorphism.
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CHD incidence, independent of established cardiovascular
risk factors. Given the heterogeneity across studies, we
further utilized the MR approach. This approach has been
successful in supporting (low-density lipoprotein cholesterol)
and refuting (HDL-C) causal links to CHD that mirror clinical
trial results.47,48 The results of our MR study do support a
causal link between PAI-1 and CHD. In addition, the MR
analyses also suggest a casual effect of PAI-1 levels on blood
glucose levels and HDL-C levels. Our study represents a
comprehensive investigation of the effect of PAI-1 on CHD
and its risk factors in well-powered population samples,
suggesting potential mechanisms for further investigation or
potential intervention. We investigated the association
between PAI-1 and incident CHD via systematic meta-analysis
using current publications. Additionally, this study is the ﬁrst
to report the causality of PAI-1 on CHD and CHD risk factors
using GWAS summary statistics. By leveraging large sample
sizes reaching over 60 000 cases and 120 000 controls from
GWAS consortia, we ﬁnd a robust causal association of PAI-1
with CHD.
A key assumption for the MR approach is that genetic
variants employed as the IV can only be associated with the
outcome (CHD) through the biomarker (PAI-1). The causal
effect of PAI-1 on CHD suggested by the MR approach should
be interpreted under this assumption. In addition, further
functional studies are required to understand the mechanism
of the causal association between PAI-1 and CHD. As a protein
biomarker, the genetic locus encoding the PAI-1 transcript has
clear biological function in determining circulating PAI-1 levels.
The 4G/5G polymorphism in the promoter region of SERPINE1
has been consistently reported to be a functional variant
inﬂuencing PAI-1 expression.27,49 Knockout of Serpine1, a
mouse ortholog, creates PAI-1 deﬁciency.50 Therefore, when
exploring whether metabolic risk factors and subclinical
atherosclerosis are mediators of potential PAI-1 effects on
CHD, we only used the SERPINE1 locus SNPs as an IV.
Our study is the ﬁrst evidence to suggest a causal
association of PAI-1 on increased fasting glucose. This
indicates PAI-1 may play a role in glucose regulation and is
consistent with previous population studies that reported
positive correlations between circulating PAI-1 and glucose
levels.6,51,52 In addition to observational studies, experimental
studies showed that PAI-1 deﬁciency via genetic knock-out or
pharmacological inhibition can suppress the levels of blood
glucose in mice.53,54 MR analysis of PAI-1 with type 2
diabetes mellitus had a consistent effect direction with what
is expected based on the glucose ﬁndings, but was not
signiﬁcant (Table 2). This ﬁnding potentially suggests a causal
pathway of PAI-1 to CHD risk, mediated by elevated glucose
level. However, a mediation test would be required to verify
this conclusion using individual-level data with genetics, PAI-1
levels, fasting glucose, and CHD in the same study population.
Somewhat surprisingly, when addressing the causal effect
of PAI-1 on measurements of obesity, we ﬁnd negative trend
effects of PAI-1 on BMI and waist–hip ratio. Adipose tissue is
one of the main tissues expressing PAI-1, and population
studies have consistently shown positive correlations
between circulating PAI-1 levels and BMI.51 Ex vivo studies
suggested the bidirectional regulation between PAI-1 and
adipocytes. For example, Crandall et al suggested that
endogenous expression of PAI-1 might regulate adipogenesis
by preventing preadipocyte migration into cell clusters.55
Halleux et al reported that the expression of PAI-1 in cultured
human adipose tissue elevated in response to glucocorti-
coids.56 Therefore, we conducted analysis on the causal effect
of BMI on PAI-1 levels. The results indicated a potential
positive causal effect of BMI on PAI-1. Taken together, we
conclude that the association between circulating PAI-1 levels
and BMI may be due to a causal effect of BMI on PAI-1 rather
than PAI-1 regulation on BMI.
Our results suggest a further positive causal effect of PAI-1
on HDL-C, which is inconsistent with observational associa-
tions in the population study.51 However, an HDL-C inﬂuence
on CHD is itself paradoxical. While observational studies
consistently report a protective association of high blood
HDL-C levels with lower CHD risk, previous MR studies show
that HDL-C is not a causal risk factor for CHD.48,57
Furthermore, a recent study has reported that a loss-of-
function variant in scavenger receptor BI (SRB1) raises HDL-C
and increases CHD risk.58 Further studies are warranted to
understand potential biological mechanisms of a PAI-1 effect
on HDL-C and whether HDL-C is an intermediary between the
PAI-1 and CHD associations.
There are several limitations of the current study. Since we
used summary GWAS statistics in the current study, we were
unable to address stratiﬁed analysis questions such as
whether there is a sex or age difference in the PAI-1-CHD
link, or whether the effect of PAI-1 on CHD differs among
obese individuals versus nonobese individuals. These are
interesting questions for future studies. In addition, our
reported observational meta-analysis between PAI-1 and CHD
is based on PAI-1 quantiles, while the causal association is
based on log-transformed PAI-1 units; therefore, the effect
size of PAI-1 on CHD in these 2 sets of analysis is not directly
comparable.
In summary, we applied several approaches to understand
the role of PAI-1 in CHD. Our results through several analyses
support a causal effect of PAI-1 on CHD onset, potentially
mediated by blood glucose dysfunction. Furthermore, our
results and those of others suggest that PAI-1 may be
interlocked with obesity, and potentially HDL-C in complex
feedback relationships. Our study adds to evidence on the
role of PAI-1 in pathogenesis of CHD and suggests this
pathway may be a good target for CHD treatment.
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Methods for causal effect of BMI on PAI-1 
To further investigate our findings on the negative direction of effect of PAI-1 on BMI, which runs 
counter to some prior evidence,1 we explored the causal effect of BMI on PAI-1. Locke et al. reported 77 
independent genome-wide significant loci associated with BMI in 322,154 individuals of European 
ancestry.2 We applied the MR approach using all 77 loci as an instrumental variable (IV) using the 
inverse variance weighted (IVW) method described in our main article. Two sensitivity analyses were 
further adopted to examine potential pleiotropic effects of the selected IV. In the first sensitivity analysis, 
we used the MR-Egger method.3 In this method, an Egger regression, which is commonly used to detect 
small study bias, was used to detect the potential bias of pleiotropic effects in the MR. The beta 
coefficient in the MR-Egger is considered as a causal effect after correcting for pleiotropic effects. The 
intercept of the Egger regression provides information on the directional pleiotropic effect in the IV 
(right panel in Table S3).3 In the second sensitivity analysis, we investigated whether the causal effect 
was consistent when only 50% of the SNPs are assumed to be valid in the IV, an approach known as 
weighted median estimator.4  
 
Results for causal effect of BMI on PAI-1 
We found that increasing 1 unit of BMI was causally associated with a 0.21 unit increase of log-
transformed PAI-1 (beta, 0.21, 95% CI, 0.13, 0.29; Table S3). The result was consistent when the MR-
Egger method was applied (beta, 0.21, 95% CI, 0.02, 0.41; Table S3), with little influence of pleiotropic 
effect as indicated by the intercept (beta, -0.0002, P-value, 0.949). The median estimator was also in 
agreement with the other two analyses (beta, 0.22, 95% CI, 0.09, 0.36; Table S3). Taken together, our 
results support a robust positive causal effect of BMI on PAI-1.  






Table S1. Publications included in the observational meta-analysis 
Study PMID Adjustment in the multiple-variable model 
Thögersen et al, 19985 9826309 Age, sex, diabetes, smoking, hypertension, BMI, Cholesterol, and ApoA-1. 
Cushman et al, 19996 10073948 Hypertension, smoking status, race (white or nonwhite), diabetes, and body mass index. 
Söderberg et al, 19997 10583712 
BMI, hypertension, history of diabetes, daily smoking habits, cholesterol levels, leptin, apo A-1, 
apo B, and insulin. 
Folsom et al, 20018 11304480 
Age, race, and sex, smoking status (never, former, current), total cholesterol, HDL cholesterol, 
systolic blood pressure, use of antihypertensive medication, and diabetes. 
Thøgersen et al, 20049 15167204 N/A (dichotomous analysis). 
Smith et al, 200510 16286603 
Age, sex, race, hypertension, diabetes mellitus, total cholesterol, HDL, cigarette smoking and 
alcohol intake. 
Aleksic et al, 200911 18342864 
Age, sex, race, hypertension, diabetes mellitus, total cholesterol, HDL, cigarette smoking and 
alcohol intake. 
Thøgersen et al, 200912 19357504 Age, smoking, CRP, t-PA, creatinine. 
Luc et al, 201013 19823188 
Diabetes, hypertension, smoking status, total and high-density lipoprotein (HDL) cholesterol 
and triglycerides. 
Meltzer et al, 201014 20413657 Age, HDL and total cholesterol, triglycerides, BMI, and diabetes. 
Yano et al, 201315 23551722 
Sex, body mass index, history of diabetes, history of hyperlipidemia, and 24-hour pulse rate, 
high levels of high-sensitivity C-reactive protein, prothrombin fragment 1+2. 
De Luca et al, 201316 24004495 
Duration of time between the date of samples and the analysis time, age, total cholesterol, 
HDL. 






Knudsen et al, 201417 24566095 Viral load and a high (Data collection on Adverse events of Anti-HIV Drugs) D:A:D risk score. 
Tofler et al, 201618 26896607 
Age, sex, systolic blood pressure, anti-hypertensive therapy, BMI, diabetes, cigarette smoking, 










Table S2. SNPs involved in the genetic risk scores as instrumental variable for PAI-1 
 
* Allele freq in PAI-1 and CHD reported the allele frequency of the risk allele in the study samples for PAI-1 and CHD respectively.  
** Effect of SNPs on PAI-1 is reported as beta coefficient (with standard error) from Huang et al, 2012.19 
*** Effect of SNPs on CHD is reported as log-transformed Odds ratio (with standard error) from Nikpay et al, 2015.20  
SNPid Chr:position(hg19) Risk/Other alleles Allele freq in PAI-1* Allele freq in CHD* Effect on PAI-1** Effect on CHD*** 
SNPs involved in the single locus instrumental variable 
rs2227631 chr7:100,769,538 A/G 0.592 0.563 0.076 (0.010) 0.008 (0.009) 
rs2075756 chr7:100,466,441 A/G 0.282 0.279 0.058 (0.010) 0.027 (0.010) 
rs12672665 chr7:100,483,731 A/G 0.479 0.474 0.047 (0.009) 0.012 (0.009) 
rs757718 chr7:100,792,810 T/C 0.093 0.118 0.081 (0.016) -0.013 (0.017) 
SNPs involved in the multi locus instrumental variable 
rs2227631 chr7:100,769,538 A/G 0.592 0.563 0.076 (0.010) 0.008 (0.009) 
rs6976053 chr7:100,512,119 T/C 0.479 0.476 0.054 (0.009) 0.019 (0.009) 
rs6486122 chr11:13,361,524 T/C 0.689 0.638 0.051 (0.009) 0.034 (0.010) 
rs11128603 chr3:12,385,828 A/G 0.898 0.870 0.086 (0.016) -0.001 (0.014) 


















Causal effect of BMI on PAI-1 
 
Directional pleiotropic effect 
Method Beta 95% CI P-value Beta  P-value 
Primary MR analysis 
   
    
IVW approach 0.21 0.13, 0.29 4.31E-07 N/A N/A 
Sensitivity analysis           
MR_Egger 0.21 0.02, 0.41 0.034 -0.0002 0.949 
Weighted median estimator 0.22 0.09, 0.36 0.001 N/A N/A 
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